Drug Landscape ›
Sildenafil 20 MG ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 100
Most-reported reactions
Death — 34 reports (34%) Hospitalisation — 16 reports (16%) Pneumonia — 9 reports (9%) Cardiac Disorder — 7 reports (7%) Cardiac Failure Congestive — 6 reports (6%) Dyspnoea — 6 reports (6%) Therapy Cessation — 6 reports (6%) Therapy Interrupted — 6 reports (6%) Drug Dose Omission — 5 reports (5%) Fluid Retention — 5 reports (5%)
Source database →
Sildenafil 20 MG in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Sildenafil 20 MG approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for Sildenafil 20 MG in United States?
National Taiwan University Hospital is the originator. The local marketing authorisation holder may differ — check the official source linked above.